Three cases of treatment with nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy

Jang, Shin Yi; Rhee, Ji-Young

doi:10.1016/j.ijid.2020.05.072

Cited by 83 publications

(71 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, Jang et al reported three cases of elderly patients with COVID-19 pneumonia who showed sufficient recovery with nafamostat therapy in this journal ( Jang and Rhee, 2020 ). Their successful experience would encourage its future use in COVID-19.…”

Section: Introductionmentioning

confidence: 88%

Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation

Takahashi¹,

Yoneda²,

Ueda³

et al. 2021

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Highlights Antiviral treatment did not show efficacy for hypoxemia and DIC in COVID-19 patient. Heparin and nafamostat combination therapy showed dramatic efficacy on the illness. Mechanisms by which nafamostat is effective for COVID-19 have been fully explained. This would be an instructional lecture on nafamostat therapy for COVID-19 patients.

show abstract

Section: Introductionmentioning

confidence: 88%

Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation

Takahashi¹,

Yoneda²,

Ueda³

et al. 2021

International Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…Nafamostat is reportedly effective against COVID-19 [ 84 , 85 ], but the significance of this agent in combination with heparin is hoped to be verified. Nafamostat administered during ECMO treatment (heparin is required) is inevitably administered in combination with heparin.…”

Section: Three Reasons Nafamostat Is Effective Against Covid-19mentioning

confidence: 99%

COVID-19-associated coagulopathy and disseminated intravascular coagulation

2020

View full text Add to dashboard Cite

The pathology of coronavirus disease 2019 (COVID-19) is exacerbated by the progression of thrombosis, and disseminated intravascular coagulation (DIC), and cytokine storms. The most frequently reported coagulation/fibrinolytic abnormality in COVID-19 is the increase in d -dimer, and its relationship with prognosis has been discussed. However, limits exist to the utility of evaluation by d -dimer alone. In addition, since the coagulation/fibrinolytic condition sometimes fluctuates within a short period of time, regular examinations in recognition of the significance of the examination are desirable. The pathophysiology of disseminated intravascular coagulation (DIC) associated with COVID-19 is very different from that of septic DIC, and both thrombotic and hemorrhagic pathologies should be noted. COVID-19 thrombosis includes macro- and microthrombosis, with diagnosis of the latter depending on markers of coagulation and fibrinolysis. Treatment of COVID-19 is classified into antiviral treatment, cytokine storm treatment, and thrombosis treatment. Rather than providing uniform treatment, the treatment method most suitable for the severity and stage should be selected. Combination therapy with heparin and nafamostat is expected to develop in the future. Fibrinolytic therapy and adsorption therapy require further study

show abstract

“…Baricitinib Inflammatory diseases, rheumatoid Arthritis 90,91 Reducing inflammatory responses, 90,91 having a greater efficiency in combination with RDV and LPV-RTV, 93 having the possibility of creating anemia 95,96 Corticosteroids (CSs) Inflammatory diseases 98 Reducing mortality, 102 having short-term or long-term side effects Anakinra Inflammatory diseases 108 Having good performance, reducing mortality, [110][111][112] Tocilizumab (TCZ) Inflammatory diseases, rheumatoid arthritis 116 Showing significant clinical progress, reducing inflammatory markers, reducing mortality, reducing the risk of invasive mechanical ventilation, improving oxygen delivery in patients, having few side effects [117][118][119][120][121][122][123] Anticoagulants Heparin Coagulation problems 130 Reducing mortality, 129 having side effects including drug resistance and heparin-induced thrombocytopenia (HIT) 130,131 Nafamostat mesylate Coagulation problems 134 Having the ability for in vitro inhibition of SARS-CoV-2 S protein-mediated cell fusion and its infection, [132][133][134] improving clinical conditions in patients in need of supplementary oxygen therapy. 135 Arbidol (ARB)…”

Section: Immune Modulatorsmentioning

confidence: 99%

“…[132][133][134] It has also been reported that the use of this safe drug has improved clinical conditions in COVID-19 patients needing supplementary oxygen therapy. 135…”

Section: Heparinmentioning

confidence: 99%

<p>Current Options in the Treatment of COVID-19: A Review</p>

Teimury¹,

Khaledi²

2020

RMHP

View full text Add to dashboard Cite

Novel Coronavirus, also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in December 2019 in China and spread rapidly all around the world infecting many people. To date, no specific vaccines and drugs have been developed for this disease. Also, due to the COVID-19 pandemic and high prevalence of the infected patients, the drugs and the therapies of other past viral epidemics have been used for this disease. Many studies have been performed on the specific treatments to find whether or not they are effective on COVID-19 patients. In this review, we collected information about the most widely used drugs to treat COVID-19 (coronavirus disease 2019) belonging to groups of antivirals, antibiotics, immune modulators, and anticoagulants. Some of these compounds and drugs were used directly by inpatients, so researchers have examined others in laboratory conditions. This study considered the pros and cons of using these treatments separately and together and compared their results. By studying this review, we hope to provide useful information for researchers.

show abstract

Three cases of treatment with nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy

Cited by 83 publications

References 6 publications

Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation

Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation

COVID-19-associated coagulopathy and disseminated intravascular coagulation

<p>Current Options in the Treatment of COVID-19: A Review</p>

Contact Info

Product

Resources

About